Final enrollment concludes for Spark Biomedical's pivotal study investigating a non-invasive, drug-free neurostimulation therapy aimed at improving treatment retention for adults with opioid use disorder.
The investment will support the company’s core areas of bioelectronic medicine, including neurological health, hemostasis, and women’s health.
Clinical enrollment concludes for Spark Biomedical’s pivotal trial investigating a non-invasive, drug-free neurostimulation treatment for newborns born with NOWS.
